Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332 (21 January), doi:10.1136/bmj.332.7534.0-c
We now know that inflammation in patients with rheumatoid arthritis should be suppressed as early as possible and treatment has become more effective, but protocols are needed in primary and secondary care for referral of patients with new inflammatory arthritis. In a clinical review on treatment of rheumatoid arthritis (p 152), Emery revisits disease modifying antirheumatic drugs; explores the advantages, opportunities, and problems of biological agents (TNF-
antagonists); and looks at two new drugs that have been submitted for licence.
|
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?